AAPG Ascentage: Bozor kapitallashuvining balans qiymatiga nisbati

Ascentage (AAPG) - korporativ logo

Ascentage Pharma Group (AAPG) dori vositalarini ishlab chiqish jarayonida kimyoviy izlarni minimallashtirib, chiqindilarni yo'q qilish qoidalariga qat'iy rioya qilgan holda ekologik toza yondashuvni saqlab qolmoqda. GURU.Markets platformasidagi ushbu tarixiy narxlar grafigi joriy tendentsiyani tasdiqlaydi, bunda ko'rsatkich 16.67 darajasida turibdi. Xitoylik ishlab chiquvchi narxlari hukumat tomonidan qoplanish orqali tartibga solinadigan noyob ingibitorlarni patentlamoqda. Biznes hozirda tadqiqot bosqichida bo'lib, bu kapitalizatsiya birlik iqtisodiyoti emas, balki test natijalariga bog'liqligini anglatadi.

Ascentage Pharma Group (AAPG) - Bozor kapitallashuvining balans qiymatiga nisbati 25.01.2025dan 28.10.2026gacha

AAPG (Ascentage Pharma Group International): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Ascentage Pharma Group|AAPG - Tahlilchilar maqsadlari diapazoni
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Ascentage|AAPG - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Ascentage Pharma|AAPG - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati ascentage.com|AAPG - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Ascentage Pharma Group|AAPG - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Ascentage|AAPG - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Ascentage
Fundamental baholash:AAPG (Ascentage Pharma Group)
Ascentage Pharma Group International tayyor mahsulotlari

Investitsiya risklarini minimallashtirish uchun Ascentage Pharma Group (AAPG) bozor qiymatini uning moddiy aktivlari bilan solishtirish zarur bo'lib, bunda onkologiya R&D xususiyatlarini, ya'ni joriy kapital xarajatlarining dori vositalari patentlanganidan keyingi superfoyda bilan almashishini hisobga olish lozim. Bozor qiymatining kitob kapitalizatsiyasiga nisbatidagi o'zgarishlarni tahlil qilish orqali investor birja baholovini kompaniyaning sof kitob kapitali bilan solishtirib, kelajakdagi o'sish uchun to'langan premiumni aniqlaydi.

Asosiy raqobatchilar

Bozor kapitallashuvining balans qiymatiga nisbati ONC (BeiGene Ltd)|halozyme.com (HALO) - Bozor qiymatining xususiy kapitalga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati CG Oncology Inc|Bozor kapitallashuvining balans qiymatiga nisbati URGN|Bozor kapitallashuvining balans qiymatiga nisbati BCAX (Bicara Corp)|PSNL - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati erasca.com ERAS|DCTH: Bozor kapitallashuvining balans qiymatiga nisbati|YMAB - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati AURA|CADL (Candel Therapeutics, Inc.) - Bozor qiymatining balans qiymatiga koeffitsiyenti|ARAY - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati SELLAS Life Sciences Group Inc. (SLS)|Actuate Therapeutics (ACTU) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Citius Oncology Inc. (CTOR)|TuHURA Biosciences - Bozor kapitallashuvining balans qiymatiga nisbati|TARA - Kapitallashuvning sof aktivlarga nisbati|Fate Therapeutics, Inc. - Kapitallashuvning sof aktivlarga nisbati|WHWK: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati tscan.com TCRX|Champions Oncology, Inc. (CSBR) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati XBIT (XBiotech Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti CEL-SCI Corp|Bozor kapitallashuvining balans qiymatiga nisbati OSTX|Bozor kapitallashuvining balans qiymatiga nisbati RADX (Radiopharm Theranostics Ltd)|Bozor qiymatining balans qiymatiga nisbati ARTV|Balans qiymatiga nisbatan bozor kapitallashuvi Adlai Nortye Ltd ANL|VERU: Bozor kapitallashuvining balans qiymatiga nisbati|TPST - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati XLO|RENB (Renovaro) - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Mural Oncology PLC (MURA)|Kapitallashuvning balans qiymatiga nisbati Kairos Pharma Inc (KAPA)|Kapitallashuvning sof aktivlarga nisbati OnKure Therapeutics Inc|Bozor kapitallashuvining balans qiymatiga multiplikatori w2.cytomed.sg (GDTC)|Bozor kapitallashuvining balans qiymatiga nisbati CRIS (Curis)|Bozor kapitallashuvining balans qiymatiga nisbati Apollomics Inc. APLM|Bozor kapitallashuvining balans qiymatiga nisbati THAR|ADVB - Bozor qiymatining xususiy kapitalga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati GNPX|Bozor qiymatining balans qiymatiga koeffitsiyenti Calidi Biotherapeutics, Inc.|SBFM - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati XBIO|SLRX - Bozor qiymatining balans qiymatiga nisbati|Sof aktivlarga nisbatan bozor kapitallashuvi Purple Biotech Ltd (PPBT)|Bozor kapitallashuvining balans qiymatiga nisbati American Oncology Network, Inc.|Balans qiymatiga nisbatan bozor qiymati BeiGene Ltd BGNE|Checkpoint Therapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|ELEV: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati icadmed.com ICAD|IKNA (Ikena Oncology) - Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati NTBL|Kapitallashuvning sof aktivlarga nisbati Viracta|Bozor kapitallashuvining balans qiymatiga nisbati MOR|Bozor kapitallashuvining balans qiymatiga nisbati nayabiosciences.com NAYA|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma